News

Congress makes $4.5 trading stocks in a day; Here's the biggest winners

Though it isn't unheard of for a member of Congress to have not traded any stocks after getting elected while supporting tighter regulations for politicians' equities market activity, the House and the Senate are nonetheless seemingly filled with exceptionally savvy investors.

07/04/2024

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.

06/20/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Vaxxinity, Inc. (VAXX) a buy, sell, or hold?

Vaxxinity, Inc. (VAXX) can sell. Click on Rating Page for detail.

What is Vaxxinity, Inc.'s stock price?

The price of Vaxxinity, Inc. (VAXX) is 0.0005 and it was updated on 2025-01-14 11:01:23.

Is Vaxxinity, Inc. (VAXX) overvalued or undervalued?

Currently Vaxxinity, Inc. (VAXX) is in undervalued.

News

From:

To:

News
Why Is Vaxxinity (VAXX) Stock Up 39% Today? Vaxxinity (NASDAQ: VAXX ) stock is up on Friday with heavy pre-market trading of the biotechnology company's shares. That has more than 21 million shares of VAXX stock changing hands as of this writing. Fri, May. 03, 2024
Why Is Vaxxinity (VAXX) Stock Down 58% Today? Vaxxinity (NASDAQ: VAXX ) stock is falling hard on Monday after the biotechnology company announced plans to voluntarily delist its shares from the Nasdaq Exchange. Vaxxinity will file to delist its shares on April 29, 2024. Mon, Apr. 22, 2024
Vaxxinity Issues Shareholder Letter CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. Fri, Apr. 19, 2024
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act. Fri, Apr. 19, 2024
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease Thu, Mar. 28, 2024

SEC Filings

SEC Filings
Vaxxinity, Inc. (VAXX) - DEF 14C SEC Filings 05/09/2024
Vaxxinity, Inc. (VAXX) - 15-12G SEC Filings 05/09/2024
Vaxxinity, Inc. (VAXX) - EFFECT SEC Filings 05/03/2024
Vaxxinity, Inc. (VAXX) - S-8 POS SEC Filings 04/30/2024
Vaxxinity, Inc. (VAXX) - POS AM SEC Filings 04/30/2024
Vaxxinity, Inc. (VAXX) - PRE 14C SEC Filings 04/29/2024
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 04/29/2024
Vaxxinity, Inc. (VAXX) - 25 SEC Filings 04/29/2024
Vaxxinity, Inc. (VAXX) - 10-K/A - Current report SEC Filings 04/29/2024
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 04/19/2024
Vaxxinity, Inc. (VAXX) - 10-K - Current report SEC Filings 03/27/2024
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 03/14/2024
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 02/15/2024
Vaxxinity, Inc. (VAXX) - SC 13G/A SEC Filings 02/12/2024
Vaxxinity, Inc. (VAXX) - SC 13G/A SEC Filings 02/07/2024
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 12/01/2023
Vaxxinity, Inc. (VAXX) - 10-Q - Quarterly Report SEC Filings 11/08/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 11/03/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 10/11/2023
Vaxxinity, Inc. (VAXX) - 3 SEC Filings 10/11/2023
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 09/28/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 09/08/2023
Vaxxinity, Inc. (VAXX) - EFFECT SEC Filings 08/21/2023
Vaxxinity, Inc. (VAXX) - 424B3 SEC Filings 08/21/2023
Vaxxinity, Inc. (VAXX) - S-3 SEC Filings 08/09/2023
Vaxxinity, Inc. (VAXX) - 10-Q - Quarterly Report SEC Filings 08/09/2023
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 07/27/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 06/26/2023
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 06/22/2023
Vaxxinity, Inc. (VAXX) - 10-Q - Quarterly Report SEC Filings 05/09/2023
Vaxxinity, Inc. (VAXX) - S-8 POS SEC Filings 05/05/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 05/02/2023
Vaxxinity, Inc. (VAXX) - ARS SEC Filings 05/01/2023
Vaxxinity, Inc. (VAXX) - S-8 POS SEC Filings 04/28/2023
Vaxxinity, Inc. (VAXX) - S-8 SEC Filings 04/28/2023
Vaxxinity, Inc. (VAXX) - DEFA14A SEC Filings 04/28/2023
Vaxxinity, Inc. (VAXX) - DEF 14A SEC Filings 04/28/2023
Vaxxinity, Inc. (VAXX) - 3/A SEC Filings 04/28/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 04/05/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 04/04/2023
Vaxxinity, Inc. (VAXX) - 10-K - Current report SEC Filings 03/27/2023
Vaxxinity, Inc. (VAXX) - SC 13G/A SEC Filings 02/13/2023
Vaxxinity, Inc. (VAXX) - 3 SEC Filings 02/10/2023
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 02/03/2023
Vaxxinity, Inc. (VAXX) - SC 13G/A SEC Filings 01/27/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 01/25/2023
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 12/05/2022
Vaxxinity, Inc. (VAXX) - 10-Q - Quarterly Report SEC Filings 11/10/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 09/08/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 08/29/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 08/25/2022
Vaxxinity, Inc. (VAXX) - 10-Q - Quarterly Report SEC Filings 08/11/2022
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 06/24/2022
Vaxxinity, Inc. (VAXX) - 4/A SEC Filings 06/23/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 06/23/2022
Vaxxinity, Inc. (VAXX) - 3/A SEC Filings 06/23/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 06/21/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 06/14/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 06/10/2022
Vaxxinity, Inc. (VAXX) - 10-Q - Quarterly Report SEC Filings 05/09/2022
Vaxxinity, Inc. (VAXX) - DEFA14A SEC Filings 05/06/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 05/05/2022
Vaxxinity, Inc. (VAXX) - DEF 14A SEC Filings 05/02/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 04/28/2022
Vaxxinity, Inc. (VAXX) - SC 13G SEC Filings 04/27/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 04/27/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 04/04/2022
Vaxxinity, Inc. (VAXX) - 3 SEC Filings 04/04/2022
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 03/28/2022
Vaxxinity, Inc. (VAXX) - 10-K - Current report SEC Filings 03/24/2022
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 03/22/2022
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 03/21/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 03/15/2022
Vaxxinity, Inc. (VAXX) - SC 13G SEC Filings 02/09/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 01/26/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 01/11/2022
Vaxxinity, Inc. (VAXX) - 3 SEC Filings 01/11/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 01/06/2022
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 01/05/2022
Vaxxinity, Inc. (VAXX) - 3 SEC Filings 01/05/2022
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 01/04/2022
Vaxxinity, Inc. (VAXX) - 10-Q - Quarterly Report SEC Filings 12/23/2021
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 12/14/2021
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 11/18/2021
Vaxxinity, Inc. (VAXX) - 8-K - Current report SEC Filings 11/17/2021
Vaxxinity, Inc. (VAXX) - S-8 SEC Filings 11/15/2021
Vaxxinity, Inc. (VAXX) - 4 SEC Filings 11/15/2021
Vaxxinity, Inc. (VAXX) - EFFECT SEC Filings 11/12/2021
Vaxxinity, Inc. (VAXX) - EFFECT SEC Filings 11/12/2021
Vaxxinity, Inc. (VAXX) - 424B4 SEC Filings 11/12/2021
Vaxxinity, Inc. (VAXX) - FWP SEC Filings 11/10/2021
Vaxxinity, Inc. (VAXX) - CERT SEC Filings 11/10/2021
Vaxxinity, Inc. (VAXX) - 8-A12B SEC Filings 11/10/2021
Vaxxinity, Inc. (VAXX) - 3 SEC Filings 11/10/2021
Vaxxinity, Inc. (VAXX) - CORRESP SEC Filings 11/08/2021
Vaxxinity, Inc. (VAXX) - S-1/A SEC Filings 11/05/2021
Vaxxinity, Inc. (VAXX) - CORRESP SEC Filings 11/05/2021
Vaxxinity, Inc. (VAXX) - UPLOAD SEC Filings 10/20/2021
Vaxxinity, Inc. (VAXX) - CORRESP SEC Filings 10/15/2021
Vaxxinity, Inc. (VAXX) - S-1 SEC Filings 10/08/2021
Vaxxinity, Inc. (VAXX) - CORRESP SEC Filings 10/08/2021
Vaxxinity, Inc. (VAXX) - UPLOAD SEC Filings 09/30/2021
Vaxxinity, Inc. (VAXX) - DRSLTR SEC Filings 09/16/2021
Vaxxinity, Inc. (VAXX) - DRS/A SEC Filings 09/16/2021
Vaxxinity, Inc. (VAXX) - UPLOAD SEC Filings 09/02/2021
Vaxxinity, Inc. (VAXX) - DRSLTR SEC Filings 08/13/2021
Vaxxinity, Inc. (VAXX) - DRS SEC Filings 08/06/2021
Vaxxinity, Inc. (VAXX) - D SEC Filings 03/31/2021
Vaxxinity, Inc. (VAXX) - D SEC Filings 03/17/2021

Press Releases

StockPrice Release
Vaxxinity ub-312 parkinson's trial results published in nature medicine 06/20/2024
Vaxxinity issues shareholder letter 04/19/2024
Vaxxinity announces intention to voluntarily delist and deregister its class a common stock 04/19/2024
Vaxxinity to present clinical data at the annual academy of neurology 2024 annual meeting 03/28/2024
Vaxxinity reports fourth quarter and full-year 2023 financial results and provides corporate updates 03/27/2024
Vaxxinity announces positive target engagement data from phase 1 clinical trial for parkinson's disease at ad/pd™ 2024 03/07/2024
Vaxxinity's cholesterol vaccine candidate successfully lowers ldl-c: preclinical data published 02/15/2024
Vaxxinity to present clinical and preclinical pipeline data at ad/pd 2024 02/13/2024
Vaxxinity announces research collaboration on active immunotherapies for neurodegenerative diseases with university of florida 01/30/2024
Vaxxinity announces collaboration on space medicine research with university of central florida 01/18/2024
Vaxxinity to present at the 2024 j.p. morgan healthcare conference 01/03/2024
Vaxxinity to present at upcoming november medical and investor conferences 11/13/2023
Vaxxinity reports third quarter 2023 financial results and provides corporate update 11/08/2023
Vaxxinity to present at upcoming investor conferences in september 08/29/2023
Vaxxinity announces publication of ub-311 safety, tolerability, immunogenicity, and clinical efficacy data from phase 2a trial in alzheimer's disease 08/10/2023
Vaxxinity reports second quarter 2023 financial results and provides corporate update 08/09/2023
Vaxxinity appoints peter powchik, m.d., to executive vice president, global scientific director 07/27/2023
Vaxxinity to present at world vaccine congress, american academy of neurology, and bna2023 festival of neuroscience in april 03/28/2023
Vaxxinity joins transcelerate research and development consortium 03/21/2023
Vaxxinity announces first subjects dosed in phase 1 clinical trial of vxx-401, investigational anti-pcsk9 vaccine to treat hypercholesterolemia 03/20/2023
Vaxxinity to present at upcoming march scientific and medical conferences 03/02/2023
Vaxxinity announces board appointments and establishes new headquarters in florida 02/01/2023
Vaxxinity announces positive topline pivotal phase 3 covid-19 booster data for ub-612 12/02/2022
Vaxxinity reports third quarter 2022 financial results and provides corporate update 11/10/2022
Vaxxinity announces first subjects dosed in phase 1 clinical trial of ub-313 for preventive treatment of migraine 09/13/2022
Vaxxinity reports second quarter 2022 financial results and provides corporate updates 08/11/2022
Vaxxinity ceo mei mei hu speaking at white house summit on the future of covid-19 vaccines 07/25/2022
Cepi to co-fund vaxxinity's pivotal phase 3 ub-612 heterologous booster trial to combat sars-cov-2 variants 04/06/2022
Vaxxinity reports fourth quarter and full-year 2021 financial results and provides corporate updates 03/24/2022
Vaxxinity appoints dr. peter powchik to board of directors 03/21/2022
Vaxxinity's covid-19 vaccine candidate ub-612 produces high levels of neutralizing antibodies against omicron and other variants of concern 02/11/2022
Vaxxinity announces first parkinson's disease patient dosed in part b of phase 1 clinical trial of ub-312 01/12/2022
Vaxxinity reports third quarter 2021 financial results and provides corporate updates 12/23/2021

More Headlines

News
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. 03/27/2024
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024 UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients 03/07/2024
Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. 02/15/2024
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease and preclinical data from its anti-tau program in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal. 02/13/2024
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida's (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option. 01/30/2024
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases. 01/18/2024
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 10:30am PST. 01/03/2024
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines. 12/11/2023
Vaxxinity to Present at Upcoming November Medical and Investor Conferences CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November. 11/13/2023
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. 11/08/2023
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) The heavy selling pressure might have exhausted for Vaxxinity, Inc. (VAXX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. 09/07/2023
Vaxxinity to Present at Upcoming Investor Conferences in September CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in New York in September: 08/29/2023
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease Phase 2a data published in The Lancet's eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clinic UB-311 could offer multiple competitive advantages over licensed passive immunotherapies, including less frequent dosing, a more convenient mode of administration, improved accessibility and cost-effectiveness, and potentially lower rates of ARIA-E CAPE CANAVERAL, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the print publication of Phase 2a clinical trial data in The Lancet's eBioMedicine (Volume 94, 104665, August 2023), stating that UB-311 “was safe and well-tolerated,” with early clinical data demonstrating a trend for slowing cognitive decline in mild Alzheimer's disease (AD). 08/10/2023
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. 08/09/2023
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team 07/27/2023
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress 03/28/2023
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference 03/02/2023
The 5 Best and Worst Performing Small-Cap Stocks in January 2023 Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market. 02/13/2023
Why Shares of Vaxxinity Jumped This Week Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one. 01/19/2023
Vaxxinity: Potential Strong Upsides Ahead We may not be at the end credits for COVID-19 virus. Shares of Vaxxinity, Inc., like most biotechs, have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geopolitical. 01/17/2023
Why Shares of Vaxxinity Soared This Week Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity. 12/02/2022
Why Did Vaxxinity (VAXX) Stock Gain 80% Today? VAXX stock gained more than 80% on Friday after Vaxxinity announced it has enrolled patients for the next part of its trials. The post Why Did Vaxxinity (VAXX) Stock Gain 80% Today? 04/29/2022
Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate. 01/13/2022
Vaxxinity Stock (VAXX): Why The Price Went Up Today The stock price of Vaxxinity Inc (NASDAQ: VAXX) increased by 29.67% today. This is why it happened. 01/12/2022
Vaxxinity Has a Rough Public Debut Investors have trouble valuing the biotech's IPO. 11/28/2021
Vaxxinity enjoys warm Wall Street reception as stock trades 20% above IPO price Vaxxinity Inc. VAXX, +19.23% started its public life with a big rally, as the Texas-based biotechnology company's stock was trading more 21.2% above its initial public offering price. The company said overnight that its IPO of 6.0 million shares, down from previous expectations of a 6.7-million share offering, priced at $13 a share, below the expected range of between $14 and $16 a share. 11/11/2021

Unlock

VAXX Ratings Summary

VAXX Quant Ranking